enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Bedinvetmab - Wikipedia

   en.wikipedia.org/wiki/Bedinvetmab

   Half the dogs received bedinvetmab and half the dogs received a sterile saline injection every 28 days for a total of three doses. [5] Before treatment and on various days throughout the study, owners used the Canine Brief Pain Inventory (CBPI) assessment tool to measure the severity of the dog's pain and the degree to which the pain interfered ...

3. Cefovecin - Wikipedia

   en.wikipedia.org/wiki/Cefovecin

   Cefovecin is an antibiotic of the cephalosporin class, licensed for the treatment of skin infections in cats and dogs. It is marketed by Zoetis under the trade name Convenia. It is used to treat skin infections caused by Pasteurella multocida in cats, and Staphylococcus intermedius and Streptococcus canis in dogs. The advantage of using a long ...

4. Hepatitis C - Wikipedia

   en.wikipedia.org/wiki/Hepatitis_C

   There is no vaccine against hepatitis C. [1] [9] Prevention includes harm reduction efforts among people who inject drugs, testing donated blood, and treatment of people with chronic infection. [4] [10] Chronic infection can be cured more than 95% of the time with antiviral medications such as sofosbuvir or simeprevir.

5. Here's What Hepatitis C Actually Is—and How You Get It - AOL

   www.aol.com/lifestyle/heres-hepatitis-c-actually...

   Side effects include headaches, diarrhea, nausea and fatigue. Which of these three you take often comes down to what your insurance covers and what your personal preferences are, says Dr. Dieterich.

6. Understanding hepatitis C: A growing public health concern - AOL

   www.aol.com/news/understanding-hepatitis-c...

   Mar. 14—Hepatitis C is a liver infection caused by the hepatitis C virus. It is becoming a big public health concern in many counties, including Lawrence County, encouraging us to review some ...

7. Ledipasvir - Wikipedia

   en.wikipedia.org/wiki/Ledipasvir

   Ledipasvir is a drug for the treatment of hepatitis C that was developed by Gilead Sciences. [1] After completing Phase III clinical trials, on February 10, 2014, Gilead filed for U.S. approval of a ledipasvir/sofosbuvir fixed-dose combination tablet for genotype 1 hepatitis C. [2] [3] The ledipasvir/sofosbuvir combination is a direct-acting antiviral agent that interferes with HCV replication ...